NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split

Written by Emily J. Thompson, Senior Investment Analyst

NKGN%

Updated: Mar 04 2025

0mins

Delisting from Nasdaq: NKGen Biotech will be delisted from the Nasdaq Global Market due to non-compliance with listing requirements, effective after trading on March 4.
Transition to OTC Markets: The company's stock will begin trading on the OTC Markets Group starting March 5, aiming for the OTCQX platform while avoiding a previously planned reverse stock split.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Micron Technology to Acquire Powerchip's P5 Fab for $1.8 Billion

Micron Technology Acquires Powerchip's P5 Fab for $1.8 Billion

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch